AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02642419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)
Description: * Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~* Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~  * Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~ * Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~ * Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk.
Study NCT02642419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
Study NCT01559506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Barrier System device
Description: Device is deployed adjacent to the surgery site and activated.
Study NCT03582956 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Euglycemic hyperinsulinemic clamp with tracer enhancement
Description: To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.
Study NCT03582956 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Euglycemic hyperinsulinemic clamp with tracer enhancement
Description: A comparison control group of 36 lean young adults with T1D will also be enrolled, since they will be unaffected by the adverse metabolic effects of puberty or obesity.
Study NCT03852433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via subcutaneous injections
Study NCT02929914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia and rubber dam isolation
Description: Local anesthesia was performed. Tooth was isolated using a rubber dam isolation in order to collect the dentin samples.
Study NCT03852433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a (PEG-IFN alfa)
Description: Administered via subcutaneous injections
Study NCT01514123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion once every 2 weeks
Study NCT00660088 — intervention group
Intervention type: OTHER
Intervention: Ketasyn
Description: 10g for 7 days, 20g for 7 or 14 days
Study NCT02929914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incomplete caries removal and microbiological samples collection
Description: Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed.
Study NCT02929914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dentin washed with sodium 0.9% saline
Description: The remaining dentin was dipped in sodium 0.9% saline for 2min.
Study NCT02929914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy
Description: The remaining dentin was disinfected with aPDT for 2 min.
Study NCT02929914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbiological samples collection and Indirect pulp treatment
Description: A new dentin collection was performed after this treatment at another site of the cavity. Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin (Z350,3M).
Study NCT01128842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg once daily by mouth.
Study NCT01128842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500 mg/m\^2 twice daily by mouth.
Study NCT01522508 — intervention group
Intervention type: PROCEDURE
Intervention: tetanic stimulation
Description: as test stimulus a painful tetanic stimulation is used
Study NCT01686828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/mL administered subcutaneously (at Day 0, Week 2)
Study NCT00578838 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance
Description: Patients each will undergo 4 MR examinations as part of this research study.
Study NCT01321996 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 68Ga-DOTA-NOC PET/CT
Description: procedure: PET/CT scan with 68Ga-DOTA-NOC
Study NCT02273154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
Study NCT02273154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: MDD patients with anxiety disorder take paroxetine (20-60mg/d)
Study NCT02273154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: MDD patients with anxiety disorder take paroxetine (20-60mg/d)
Study NCT01686828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone 1.62% gel
Description: Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
Study NCT01686828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
Study NCT01686828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo gel (for Testosterone 1.62% gel)
Description: placebo gel manufactured to mimic Testosterone 1.62% gel
Study NCT01686828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill (for Letrozole)
Description: Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
Study NCT00006222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Study NCT02184143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBPT
Description: Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
Study NCT00578838 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance
Description: You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
Study NCT03695055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance therapy post-HSCT
Description: Rituximab vs DPP/DCEP-G vs observation
Study NCT03695055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance therapy post-HSCT
Description: Rituximab vs DPP/DCEP-G vs observation
Study NCT00978887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retorna
Description: Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
Study NCT02184143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Patient education
Study NCT03782818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib up to 300 mg BID for 24 weeks
Study NCT00748059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standing or upright tilt
Description: stand upright or tilt table test
Study NCT00748059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneurography
Description: Recording from sympathetic nerve
Study NCT00748059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QSweat
Description: quantitative sweat testing
Study NCT00748059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neck cuff stimulation
Description: Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
Study NCT00748059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine
Description: IV Pharmacological Testing~phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect
Study NCT00748059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine,yohimbine,metoclopramide,alpha-methyldopa
Description: Oral Pharmacological Testing~clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo
Study NCT00748059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BodPod
Description: Determination of body composition
Study NCT00748059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eye exam
Description: Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:~1. 0.5% proparacaine (Alcaine, Allergan, Inc)~2. Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)~3. 0.5%, 1% tropicamide (Mydriacyl, Alcon)~4. Over-the-counter preservative-free artificial tears~5. 0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)~6. 1% cyclopentolate hydrochloride (Alcon)
Study NCT00748059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleep study
Description: Recording of sleep pattern overnight
Study NCT00748059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pain response testing
Description: Subjects will rate the quality and intensity of 2 pain tasks.
Study NCT00748059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metabolic chamber
Description: Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
Study NCT00748059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain function studies
Description: Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
Study NCT00748059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bicycle Exercise Test
Description: Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
Study NCT02626819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE! Toward Your Goals
Description: Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
Study NCT00978887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
Study NCT02626819 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling.
Study NCT01995110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat meal A
Study NCT01995110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat meal B
Study NCT00867334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate and panitumumab
Description: Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
Study NCT00867334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care treatment with panitumumab
Description: Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
Study NCT02935036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADPS topical product
Description: topical product
Study NCT02935036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: topical product
Study NCT04138355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
Study NCT01148771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem
Description: 1 gram IV bolus every 24 hours (q24h) for 3 days
Study NCT01148771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ertapenem
Description: 1 gram 30 minute infusion q24h for 3 days
Study NCT03893357 — intervention group
Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Retrospective data extraction from the medical files
Study NCT01869673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face Mask
Description: Patients will be ventilated trough a face mask first and trough a oral mask thereafter
Study NCT01869673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral Mask
Description: Patients will be ventilated trough an oral mask first and trough a face mask thereafter
Study NCT03376386 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Adaptive dose-Escalated multi-modality image-guided radiotherapy
Description: FDG-PET/CT-scan will be used twice during radiotherapy for a mild dose-escalation to the less-responding parts of the tumor. By adapting the radiotherapy plan, these areas will receive 74-78 Gy.
Study NCT01995110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat meal C
Study NCT01203631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0142-0000-0002
Description: A single dose administered subcutaneously (s.c., under the skin)
Study NCT01203631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose administered subcutaneously (s.c., under the skin)
Study NCT02966769 — intervention group
Intervention type: OTHER
Intervention: Overall survival
Description: Compare overall survival between both groups.
Study NCT00542360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marketing program to motivate exercise class participation
Description: Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
Study NCT01950676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart phone application
Description: The smart phone application (Diabetes Pal), will guide patients on self-titration of insulin. Patients will be required to key in the CBG readings into the application. Up-titration of insulin dose will be carried out once every 3 days and the recommended insulin dose will be based on the mean of 3 CBG readings and a pre-specified titration algorithm. The process of using the insulin self-titration application will continue until the patient has reached the target pre-breakfast CBG.
Study NCT04040205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 200 mg will be taken by mouth twice daily.
Study NCT03191279 — intervention group
Intervention type: PROCEDURE
Intervention: First aid
Description: Open airway (head tilt, chin lift), recovery position, staunch of bleeding, prevention of hypothermia, cooling of burn, CPR
Study NCT02965664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PresbiDrops (CSF-1)
Description: PresbiDrops (CSF-1) is a topical ophthalmic drug.
Study NCT02965664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
Study NCT02502331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test Oral Cholera Vaccine
Description: Thimerosal free, manufactured at 600 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
Study NCT02502331 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Euvichol®
Description: Licensed, manufactured at 100 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
Study NCT04412434 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electroencephalography (EEG)
Description: Electroencephalography (EEG) is a painless and harmless method to record the bioelectric activity of the brain. Clinically, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time, as recorded from multiple electrodes placed on the scalp This method can be helpful in the diagnosis of many various brain diseases and pathological conditions.~For the examination, electrodes are placed on the head, using a special harmless gel, similar to gel, used in ultrasonographic studies.
Study NCT04209192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin Tromethamine 3G Sachet
Description: Is the prophylactic drug which will be used in the intervention group.
Study NCT04209192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: Is the prophylactic drug which will be used in the control group.
Study NCT02823847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening Interview
Description: Participants asked about demographic information, and questions about history of tobacco, alcohol, and mouthwash use. Interview lasts about 7 minutes.
Study NCT02823847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide Test
Description: Carbon monoxide testing given to participants at baseline. Participants blow into a device that measures the amount of carbon monoxide in the lungs.
Study NCT02823847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help Materials
Description: Participants who want to stop smoking are given referral information for a tobacco cessation program at baseline.~Participants with premalignant and malignant oral lesions \[PMOL\]) given printed materials and web-based programs for tobacco and alcohol cessation.
Study NCT02823847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visual Oral Screening Examination
Description: Intraoral exam performed under incandescent (white light) conditions at baseline, and again two weeks later.
Study NCT02823847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Fluorescent Oral Visualization Examination
Description: Intraoral exam performed under reduced room lighting with a handheld autofluorescence imaging device at baseline, and again two weeks later.
Study NCT02823847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Biopsy
Description: Premalignant and malignant oral lesions \[PMOL\]) still present 2 weeks after oral exam are biopsied.
Study NCT00668096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
Study NCT03852433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2a (PEG-IFN alfa)
Description: Administered via subcutaneous injections
Study NCT06234280 — intervention group
Intervention type: DEVICE
Intervention: Implantation of Eluvia stent
Description: Implantation of Eluvia stent
Study NCT02733250 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pembrolizumab
Description: 200mg IV Day 1 of each 21 cycles
Study NCT02733250 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nab-Paclitaxel
Description: 100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
Study NCT00570869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR Anytime
Description: These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
Study NCT02528591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oscillometric device (Arteriograph®, Medexpert)
Description: Central blood pressure recorded in the non-fistula arm using a validated oscillometric device (Arteriograph®, Medexpert).